Huizi Sha
Nanjing Drum Tower Hospital(CN)Jiangsu Cancer Hospital(CN)
Publications by Year
Research Areas
Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Monoclonal and Polyclonal Antibodies Research, Cancer Research and Treatments
Most-Cited Works
- → CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients(2016)302 cited
- → iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer(2019)123 cited
- → Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy(2014)101 cited
- → CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer(2016)97 cited
- → Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment(2018)94 cited
- → Lipid insertion enables targeted functionalization of paclitaxel-loaded erythrocyte membrane nanosystem by tumor-penetrating bispecific recombinant protein(2018)89 cited
- → Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation(2021)53 cited
- → Anti-EGFR-iRGD recombinant protein conjugated silk fibroin nanoparticles for enhanced tumor targeting and antitumor efficiency(2016)50 cited
- → Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy(2017)42 cited
- → Integration of simultaneous and cascade release of two drugs into smart single nanovehicles based on DNA-gated mesoporous silica nanoparticles(2014)36 cited